m-BACOD Treatment for intermediate- and high-grade malignant lymphomas: A Southwest Oncology Group phase II trial

B. W. Dana, S. Dahlberg, Thomas P Miller, R. J. Hartsock, S. Balcerzak, C. A. Coltman, J. O. Carden, K. Hartley, R. I. Fisher

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

One hundred six eligible patients with advanced intermediate- or high-grade malignant lymphoma were treated with methotrexate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-BACOD) in a Southwest Oncology Group phase II trial. Patients were stratified by estimated bone marrow reserve, and impaired marrow reserve patients received reduced doses of cyclophosphamide and doxorubicin. The complete remission rate for normal marrow reserve patients was 65%, while the complete remission rate for impaired marrow reserve patients was 29%. With a median follow-up period of 41 months. 64% of complete responders in the normal marrow group are disease-free 3 years after their response. Three-year survival is 61% in the normal marrow reserve group and is 29% in the impaired marrow reserve group. Eighty-seven percent of treatment courses were given in accordance with protocol dosing and schedule. For doxorubicin, relative dose intensities were 0.75 and 0.61 (normal and impaired marrow reserve arms, respectively), for cyclophosphamide, 0.76 and 0.61, and for methotrexate, 0.55 and 0.45. Serum lactic dehydrogenase (LDH) level was the only pretreatment characteristic found to have a significant effect on overall survival. Severe or greater toxicity occurred in 97% and 89% of the normal and impaired marrow reserve groups, respectively, with granulocytopenia the principal toxicity. Treatment-related fatalities occurred in 8% of patients. m-BACOD is an effective but toxic treatment program for intermediate- and high-grade malignant lymphomas.

Original languageEnglish (US)
Pages (from-to)1155-1162
Number of pages8
JournalJournal of Clinical Oncology
Volume8
Issue number7
StatePublished - Jan 1 1990
Externally publishedYes

Fingerprint

Non-Hodgkin's Lymphoma
Lymphoma
Bone Marrow
Doxorubicin
Cyclophosphamide
Therapeutics
Methotrexate
Agranulocytosis
Survival
Leucovorin
Poisons
Bleomycin
Vincristine
Dexamethasone
Appointments and Schedules
Oxidoreductases
Milk
Serum

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dana, B. W., Dahlberg, S., Miller, T. P., Hartsock, R. J., Balcerzak, S., Coltman, C. A., ... Fisher, R. I. (1990). m-BACOD Treatment for intermediate- and high-grade malignant lymphomas: A Southwest Oncology Group phase II trial. Journal of Clinical Oncology, 8(7), 1155-1162.

m-BACOD Treatment for intermediate- and high-grade malignant lymphomas : A Southwest Oncology Group phase II trial. / Dana, B. W.; Dahlberg, S.; Miller, Thomas P; Hartsock, R. J.; Balcerzak, S.; Coltman, C. A.; Carden, J. O.; Hartley, K.; Fisher, R. I.

In: Journal of Clinical Oncology, Vol. 8, No. 7, 01.01.1990, p. 1155-1162.

Research output: Contribution to journalArticle

Dana, BW, Dahlberg, S, Miller, TP, Hartsock, RJ, Balcerzak, S, Coltman, CA, Carden, JO, Hartley, K & Fisher, RI 1990, 'm-BACOD Treatment for intermediate- and high-grade malignant lymphomas: A Southwest Oncology Group phase II trial', Journal of Clinical Oncology, vol. 8, no. 7, pp. 1155-1162.
Dana, B. W. ; Dahlberg, S. ; Miller, Thomas P ; Hartsock, R. J. ; Balcerzak, S. ; Coltman, C. A. ; Carden, J. O. ; Hartley, K. ; Fisher, R. I. / m-BACOD Treatment for intermediate- and high-grade malignant lymphomas : A Southwest Oncology Group phase II trial. In: Journal of Clinical Oncology. 1990 ; Vol. 8, No. 7. pp. 1155-1162.
@article{ded085e931dc42299e747fb72011e9da,
title = "m-BACOD Treatment for intermediate- and high-grade malignant lymphomas: A Southwest Oncology Group phase II trial",
abstract = "One hundred six eligible patients with advanced intermediate- or high-grade malignant lymphoma were treated with methotrexate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-BACOD) in a Southwest Oncology Group phase II trial. Patients were stratified by estimated bone marrow reserve, and impaired marrow reserve patients received reduced doses of cyclophosphamide and doxorubicin. The complete remission rate for normal marrow reserve patients was 65{\%}, while the complete remission rate for impaired marrow reserve patients was 29{\%}. With a median follow-up period of 41 months. 64{\%} of complete responders in the normal marrow group are disease-free 3 years after their response. Three-year survival is 61{\%} in the normal marrow reserve group and is 29{\%} in the impaired marrow reserve group. Eighty-seven percent of treatment courses were given in accordance with protocol dosing and schedule. For doxorubicin, relative dose intensities were 0.75 and 0.61 (normal and impaired marrow reserve arms, respectively), for cyclophosphamide, 0.76 and 0.61, and for methotrexate, 0.55 and 0.45. Serum lactic dehydrogenase (LDH) level was the only pretreatment characteristic found to have a significant effect on overall survival. Severe or greater toxicity occurred in 97{\%} and 89{\%} of the normal and impaired marrow reserve groups, respectively, with granulocytopenia the principal toxicity. Treatment-related fatalities occurred in 8{\%} of patients. m-BACOD is an effective but toxic treatment program for intermediate- and high-grade malignant lymphomas.",
author = "Dana, {B. W.} and S. Dahlberg and Miller, {Thomas P} and Hartsock, {R. J.} and S. Balcerzak and Coltman, {C. A.} and Carden, {J. O.} and K. Hartley and Fisher, {R. I.}",
year = "1990",
month = "1",
day = "1",
language = "English (US)",
volume = "8",
pages = "1155--1162",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - m-BACOD Treatment for intermediate- and high-grade malignant lymphomas

T2 - A Southwest Oncology Group phase II trial

AU - Dana, B. W.

AU - Dahlberg, S.

AU - Miller, Thomas P

AU - Hartsock, R. J.

AU - Balcerzak, S.

AU - Coltman, C. A.

AU - Carden, J. O.

AU - Hartley, K.

AU - Fisher, R. I.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - One hundred six eligible patients with advanced intermediate- or high-grade malignant lymphoma were treated with methotrexate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-BACOD) in a Southwest Oncology Group phase II trial. Patients were stratified by estimated bone marrow reserve, and impaired marrow reserve patients received reduced doses of cyclophosphamide and doxorubicin. The complete remission rate for normal marrow reserve patients was 65%, while the complete remission rate for impaired marrow reserve patients was 29%. With a median follow-up period of 41 months. 64% of complete responders in the normal marrow group are disease-free 3 years after their response. Three-year survival is 61% in the normal marrow reserve group and is 29% in the impaired marrow reserve group. Eighty-seven percent of treatment courses were given in accordance with protocol dosing and schedule. For doxorubicin, relative dose intensities were 0.75 and 0.61 (normal and impaired marrow reserve arms, respectively), for cyclophosphamide, 0.76 and 0.61, and for methotrexate, 0.55 and 0.45. Serum lactic dehydrogenase (LDH) level was the only pretreatment characteristic found to have a significant effect on overall survival. Severe or greater toxicity occurred in 97% and 89% of the normal and impaired marrow reserve groups, respectively, with granulocytopenia the principal toxicity. Treatment-related fatalities occurred in 8% of patients. m-BACOD is an effective but toxic treatment program for intermediate- and high-grade malignant lymphomas.

AB - One hundred six eligible patients with advanced intermediate- or high-grade malignant lymphoma were treated with methotrexate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-BACOD) in a Southwest Oncology Group phase II trial. Patients were stratified by estimated bone marrow reserve, and impaired marrow reserve patients received reduced doses of cyclophosphamide and doxorubicin. The complete remission rate for normal marrow reserve patients was 65%, while the complete remission rate for impaired marrow reserve patients was 29%. With a median follow-up period of 41 months. 64% of complete responders in the normal marrow group are disease-free 3 years after their response. Three-year survival is 61% in the normal marrow reserve group and is 29% in the impaired marrow reserve group. Eighty-seven percent of treatment courses were given in accordance with protocol dosing and schedule. For doxorubicin, relative dose intensities were 0.75 and 0.61 (normal and impaired marrow reserve arms, respectively), for cyclophosphamide, 0.76 and 0.61, and for methotrexate, 0.55 and 0.45. Serum lactic dehydrogenase (LDH) level was the only pretreatment characteristic found to have a significant effect on overall survival. Severe or greater toxicity occurred in 97% and 89% of the normal and impaired marrow reserve groups, respectively, with granulocytopenia the principal toxicity. Treatment-related fatalities occurred in 8% of patients. m-BACOD is an effective but toxic treatment program for intermediate- and high-grade malignant lymphomas.

UR - http://www.scopus.com/inward/record.url?scp=0025324891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025324891&partnerID=8YFLogxK

M3 - Article

C2 - 1694233

AN - SCOPUS:0025324891

VL - 8

SP - 1155

EP - 1162

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -